Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China

International Journal of Technology Assessment in Health Care

Volumn 23, Issue 1, 2007, Pages 138-145

  Chen, Yingyao ^a   Qian, Xu ^a   Li, Jun ^a   Zhang, Jie ^a   Chu, Annie ^a   Schweitzer, Stuart O ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness analysis; Down's syndrome; Prenatal diagnosis

Indexed keywords

BODY FLUIDS; COST EFFECTIVENESS; DIAGNOSTIC PRODUCTS; PATIENT TREATMENT; PEDIATRICS;

AMNIOCENTESIS (AC); CHORIONIC VILLUS SAMPLING (CVS); DOWN'S SYNDROME; PRENATAL DIAGNOSIS;

FETAL MONITORING;

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN;

ACCURACY; ADULT; AMNIOCENTESIS; ARTICLE; BLOOD ANALYSIS; CHINA; CHORION VILLUS SAMPLING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; EVIDENCE BASED MEDICINE; FEMALE; FETUS; HEALTH CARE MANAGEMENT; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL BLOOD; PREGNANCY; PRENATAL DIAGNOSIS; SCREENING;

ADULT; CHINA; COST-BENEFIT ANALYSIS; DATA COLLECTION; DOWN SYNDROME; FEMALE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 34247536838     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307051689     Document Type: Article

References (29)

1. Bao JF, Zeng PP, Shao Y. Screening for Down's syndrome by maternal serum makers. J Qiqihar Med Coll. 2004;25:259-260.
2. Cao ZS, Gou WL. Modern obstetrics. 1st ed. Beijing: People's Health Press; 2000:34-161.
3. Chao AS, Chung CL, Wu CD, et al. Second trimester maternal serum screening using alpha fetoprotein, free beta human chorionic gonadotropin and maternal age specific risk: Result of chromosomal abnormalities detected in screen positive for Down's syndrome in an Asian population. Acta Obstet Gynecol Scand. 1999;78:393-397.
4. Chen LQ, Wang W. Birth surveillance analysis in the year of 1986 and 2001 in Dongcheng District in Beijing. Dis Surveill. 2003;18:26-27.
5. Chen YY, Qian X, Tang ZL, et al. Situation analysis of prenatal diagnosis technology utilization in China: Current situation, main issues and policy implications. 2004. Int J Technol Assess Health Care. 20:524-530.
6. Chen YY, Huang W, Du L, Tang ZL, Qian X. Current situation of premarital care and countermeasures in China. Natl Key Lab Health Technol Assess. 2005.
7. Fletcher J, Hicks NR, Kay JDS, Boyd PA. Using decision analysis to compare policies for antenatal screening for Down's syndrome. BMJ. 1995;311:351-356.
8. Gilbert RE, Augood C, Gupta R, et al. Screening for Down syndrome: Effects, safety and cost-effectiveness of first and second trimester strategies. BMJ. 2001;323:423-425.
9. Glasson EJ, Sullivan SG, Hussain R, et al. The changing survival profile of people with Down's syndrome: Implications for genetic counseling. Clin Genet. 2002;62:390-393.
10. Hu WS, Chen ML. Screening for Down's syndrome and NTD. Zhejiang Prev Med. 2003;15:34.
11. Lam YH, Ghosh A, Tang MH, et al. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong. Prenat Diagn. 1998;18:585-589.
12. Li J, Chen YY, Chen J, Zhang J, Qian X. Study on standard cost of prenatal diagnosis on Down's syndrome. Chin Health Resources. 2005;8:121-122.
13. Lin AH, Wu JM, Jiang W, Li ZH, Ye PT. Study of prenatal diagnosis for Down's syndrome by AFP and HCG in the second trimester. China Maternal Child Health. 2000;15:258-259.
14. Liu B, Gao ES. Risk factors for spontaneous abortion of Chinese married women at reproductive age. China Public Health. 2002;18:890-892.
15. Liu JT, Hao N, Sun NH, et al. Screening by maternal serum markers for Down's syndrome. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003;25:156-159.
16. National Bureau of Statistics of China. China statistical yearbook 2004. Available at: http://www.stats.gov.cn.
17. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361:1281-1289.
18. Sun DG, Jiang YT, Li X. Prenatal screening study by maternal serum screening with AFP and HCG in the second trimester. China J Fam Plann. 2003;11:674-676.
19. Tabor A, Madsen M, Obel EB, et al. Randomized controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1:1287-1293.
20. Tian GL, Cao QX, Zhu WM, Dong QY. Prenatal screening for Down's syndrome and certain fetal defects. Sh J Prev Med. 2000;12:212-213.
21. Wald NJ, Walters J, Rodeck C, et al. First and second trimester antenatal screening for Down's syndrome: The results of the serum, urine and ultrasound screening study. Health Technol Assess. 2003;7:1.
22. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. Health Technol Assess. 1998;2:75-84.
23. Wen YB, Chen KC, Xiao XF, Li XH. Birth surveillance analysis between 1990-1999 in Shantou City. Dis Surveill. 2001;16:782-783.
24. Wertz DC, Fletcher JC, Berg K. Review of ethical issues in medical genetics. World Health Organization Human Genetic Program 2001:62-64.
25. World Atlas of Birth Defects. 2nd ed. Geneva:WHO;2003:151-153.
26. Yan YL. Prenatal ultrasound diagnosis. 1st ed. Beijing: People's Health Press; 2003:440-443.
27. Yu KM, Wang TF, Zhong HL, Yang HZ. The feasibility study of maternal serum screening strategy for Down's syndrome with AFP and free HCG in the second trimester. Chin J Obstet Gynecol. 2002;37:691-692.
28. Zhang XJ, Dai OH. Serum screening for Down's syndrome in the second trimester. China Gene. 2004;12:37-38.
29. Zhuo LW, Liao C, Song SB, Tu XZ. The study of prenatal screening for Down's syndrome. China Pract Obstet Gynecol. 2004;20:414-416.